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Sample size and number of outcome
measures of veterinary randomised
controlled trials of pharmaceutical
interventions funded by different sources,
a cross-sectional study
K. J. Wareham1, R. M. Hyde1, D. Grindlay2, M. L. Brennan1 and R. S. Dean1*
Abstract
Background: Randomised controlled trials (RCTs) are a key component of the veterinary evidence base. Sample sizes
and defined outcome measures are crucial components of RCTs.
To describe the sample size and number of outcome measures of veterinary RCTs either funded by the pharmaceutical
industry or not, published in 2011.
Methods: A structured search of PubMed identified RCTs examining the efficacy of pharmaceutical interventions.
Number of outcome measures, number of animals enrolled per trial, whether a primary outcome was identified, and
the presence of a sample size calculation were extracted from the RCTs. The source of funding was identified for each
trial and groups compared on the above parameters.
Results: Literature searches returned 972 papers; 86 papers comprising 126 individual trials were analysed. The median
number of outcomes per trial was 5.0; there were no significant differences across funding groups (p = 0.133). The
median number of animals enrolled per trial was 30.0; this was similar across funding groups (p = 0.302). A primary
outcome was identified in 40.5% of trials and was significantly more likely to be stated in trials funded by a
pharmaceutical company. A very low percentage of trials reported a sample size calculation (14.3%).
Conclusions: Failure to report primary outcomes, justify sample sizes and the reporting of multiple outcome measures
was a common feature in all of the clinical trials examined in this study. It is possible some of these factors may be
affected by the source of funding of the studies, but the influence of funding needs to be explored with a larger
number of trials. Some veterinary RCTs provide a weak evidence base and targeted strategies are required to improve
the quality of veterinary RCTs to ensure there is reliable evidence on which to base clinical decisions.
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Background
Randomised controlled trials (RCTs) are one of the main
sources of evidence that can be directly used for clinical
decision-making around treatment choice. They do
however vary in quality, both in conduct and reporting,
a problem which can reduce their reliability and useful-
ness to decision-makers. One important feature of trials
is which, and how many, outcomes (or endpoints) are
used to assess the effectiveness of an intervention. An
outcome can be defined as:
“A component of a participant's clinical and
functional status after an intervention has been
applied, that is used to assess the effectiveness of an
intervention.” (www.cochrane.org/glossary)
All outcomes should be relevant and specific to the
question of interest being addressed, and, in almost all
cases, should be pre-specified prior to the trial starting
and reported in the trial protocol. Any post hoc outcome
measures should have a clear rationale for their inclu-
sion. Ideally, one single primary outcome (the outcome
considered to be the most important to relevant stake-
holders, and which the study is powered for) should be
identified, with other outcomes of interest being clearly
identified as secondary [1, 2]. Previous assessments of
the veterinary clinical trials literature, based on a number
of sampling strategies for trial selection, have demon-
strated varied reporting standards of outcome measures
and identification of primary outcomes. The proportion of
trials that identify a primary outcome in previous studies
of veterinary RCTs vary from 2% to 83% [3–7]. Under-
standing the current state of, and potential deficiencies in,
outcome reporting is crucial to improve trial design, exe-
cution, and reporting and therefore increase the reliability
of clinical trial results. The factors that affect the quality
of outcome reporting need to be identified if improve-
ments are to be made.
Another crucial factor in the reliability of RCT results
is whether the study was adequately powered to detect a
difference between two or more variables of interest
within the study. Reporting guidelines for RCTs advocate
reporting of a sample size calculation to determine the
number of subjects required to detect a clinically rele-
vant difference in a specified (primary) outcome between
two trial groups [1, 2]. Sample size calculations have
been shown in the past to be vastly underreported in the
veterinary trials literature [3–7].
In a recent study, we reported that the source of fund-
ing (pharmaceutical company or other) has an effect on
positive outcome reporting (sponsorship bias) in veterin-
ary clinical trials [8]. The impact of funding on the size
of trials and whether a sample size calculation has been
undertaken remains unclear in medical RCTs [9–11]. To
date, there has been no report of the influence of fund-
ing source on the size of veterinary RCTs and whether
primary outcomes are stated or a sample size calculation
has been undertaken. This study was done concurrently
with Wareham et al. [8] to examine further whether
funding source has an effect on other aspects of trial
design and delivery.
The aim of this study is to describe the number of out-
come measures reported, the animals included, whether
primary outcome measures are stated and sample size cal-
culations are performed in a sample of veterinary pharma-
ceutical single dose efficacy RCTs either funded by the
pharmaceutical industry or not, published in a single cal-
endar year (2011). The effect of funding source on these
aspects of trial design and delivery was then explored.
Methods
A cross-sectional study of RCTs was conducted. The tar-
get population was feline, canine, equine, bovine and
ovine RCTs where a pharmaceutical agent was the inter-
vention of interest and efficacy was assessed. The sample
population was feline, canine, equine, bovine and ovine
RCTs published in 2011 within journals indexed in
PubMed. This study was conducted in parallel with Ware-
ham et al. [8] and the search strategy and literature filter-
ing processes reported in full in that manuscript also
apply to this study The same sample of literature was used
for data extraction in both studies [8].
Search strategy and filtering of results
A structured search of PubMed was conducted in June
2013 using the “clinical trial” Publication Type combined
with the relevant species MeSH heading e.g. “clinical
trial” [publication type] AND cats [mh]. This was done
for each of the 5 species studied: cats, dogs, horses, cat-
tle and sheep. The search was limited to one calendar
year with a PubMed filter: 01/01/11 – 31/12/11. Search
results were exported into EndNote® software for filter-
ing. Papers indexed as RCTs by PubMed (“randomised
controlled trials” [publication type]) were extracted and
confirmed if, when reviewed by the authors, they were
RCTs according to the Cochrane definition below
(http://www.cochrane.org/glossary/):
“An experiment in which two or more interventions,
possibly including a control intervention or no
intervention, are compared by being randomly
allocated to participants. In most trials one
intervention is assigned to each individual but
sometimes assignment is to defined groups of
individuals (for example, in a household) or
interventions are assigned within individuals
(for example, in different orders or to different
parts of the body).”
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All publications containing RCTs, published in 2011,
and relevant to the species of interest were then
categorised into four intervention subcategories based on
the main intervention of interest of the study (Table 1 -
Level 1 exclusion criteria):
1. Pharmaceutical – consisting of an active
pharmaceutical ingredient
2. Nutritional
3. Para-pharmaceutical – including probiotics,
prebiotics, synbiotics, nutraceuticals and supplements/
vitamins/minerals if not considered part of the total
dietary ration
4. Other – including surgical interventions,
management/husbandry interventions, non-medicinal
shampoos, studies relating to diagnostic tests.
Only publications within the ‘Pharmaceutical interven-
tion’ subcategory were included in this study; these were
assessed for further eligibility for analysis according to the
second level of inclusion and exclusion criteria in Table 1.
Publications included in the analysis were therefore sin-
gle dose efficacy studies of pharmaceutical interventions
in cats, dogs, horses, cattle or sheep published in 2011.
The single dose trials were selected for analysis as it
was then possible to be certain an outcome was
assigned to a single treatment. The trials included
animals with naturally occurring and experimentally
induced disease. A single calendar year was chosen to
ensure it was feasible to complete this work within
the timeframe of the funding in a situation where the
total number of veterinary RCTs published per year is
unknown. The year 2011 was chosen, as it was hoped
that by the time the searching was done (June 2013)
the 2011 trials would be fully indexed therefore pos-
sible to locate in PubMed and any erratum reported.
In the case of a publication containing more than one
trial, each trial was included independently in the
analysis if it met all inclusion criteria.
Sources of funding
For each included trial the source of funding was cate-
gorised as one of the following:
1. Pharmaceutical company funding stated or
pharmaceutical company involvement (e.g. drug
donated by a pharmaceutical company or authors
associated with a pharmaceutical company) (P)
2. Non-pharmaceutical company funding stated (NP)
3. No funding source stated (NF)
Outcome recording
A data extraction form (Additional file 1) was used by the
authors. Outcomes mentioned in the materials and
methods section of the manuscripts were included in the
analysis; outcomes that were reported as results but not
mentioned in the methods were not included. Outcomes
that had multiple components (e.g. complete blood count,
serum biochemistry, and meat yield and meat quality
grade assessments) were classed as a single outcome each
unless specific features were relevant to the disease, in
which case these were extracted as individual outcomes.
The following information was extracted:
1) Total number of outcome results: Every result for
each unique outcome measure is included in this
total. Where multiple treatment and control groups
were used, each group containing the treatment of
interest (either alone or in combination) was
compared to its relevant control group for each
outcome measure i.e. each unique outcome measure
could actually be recorded more than once within
this total. For example, a trial measuring heart rate
and respiratory rate, which compared two different
treatment groups to a control group, would have a
total number of 4 outcome results.
Table 1 Two levels of inclusion and exclusion criteria applied to
the search results
Level 1: Inclusion criteria for
publications
Level 1: Exclusion criteria for
publications
Species of interest is cats, dogs,
horses, cattle or sheep
Not about cats, dogs, horses,
cattle or sheep
Published in 2011 E published only in 2011 if full
publication occurred in a
different calendar year
RCT according to PubMed
publication types and the
Cochrane definition
Not an RCT (not indexed as an
RCT by PubMed or not fulfilling
Cochrane definition of an RCT)
Treatment of interest is a
pharmaceutical intervention
Treatment of interest is not a
pharmaceutical agent e.g.
nutritional, surgical, animal
husbandry etc
Level 2: Inclusion criteria for
analysis of pharmaceutical RCTs
Level 2: Exclusion criteria for
analysis of pharmaceutical RCTs
Primary aim is to assess efficacy Primary aim was not to assess
efficacy (pharmacokinetic/
dynamic studies, safety studies,
physiological effects, resistance
testing, testing routes of
administration only, testing
timing of administration only)
Identifiable treatment or protocol
of interest
Treatment or protocol of interest
could not be identified
Single dose of the treatment of
interest used
Multiple doses of the treatment
of interest used/dose finding
studies
Published in English Not available in English
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2) Number of unique outcome measures: The
number of individual outcome measures mentioned
in the methods section of the manuscripts, i.e. each
mentioned outcome measure included only once in
this total. For example, a trial measuring heart rate
and respiratory rate would have a unique number of
2 outcome measures.
3) Primary outcome measure: If the primary outcome
measure was stated this was recorded. Trials reporting
only one outcome measure, or completing a sample
size calculation for one specific outcome measure
were automatically categorised as having identified a
primary outcome.
4) Number of animals: The number of animals
enrolled in each trial was recorded.
5) Sample size calculation: Reporting of a sample size
calculation was recorded as ‘yes’ or ‘no’. Post-hoc
power calculations were recorded as ‘no’.
All assessments made throughout the study were
agreed upon by two authors (KW and RH/RD) with any
disputes resolved by a third author (RD/RH). The
authors who undertook the assessments of the studies
are all veterinary surgeons with methodological expertise
in study design and critical appraisal.
Statistical analysis
Categorical data were presented descriptively as raw
numbers and percentages. Numerical discrete data that
were not normally distributed were presented as me-
dian, inter-quartile range (IQR) and range (R). Within a
data set, if some subsets of data were non-normally dis-
tributed, all were presented as median, IQR and R.
Statistical comparisons between funding categories for
the number of outcomes measured, number of unique
outcome measures, and the number of animals in the
trials, were made using an independent samples
Kruskal-Wallis test with a significance level of 0.05.
Statistical comparisons between funding categories for
whether a primary outcome was stated or not and
whether a sample size calculation was done or not
were made using Fishers Exact test with a significance
level of 0.05. The NP and NF groups were sometimes
combined and compared to the P group (the group
od interest) as there were far more trials stated to be
funded by pharmaceutical companies than other
sources, Results for different species are described
only and were not compared statistically due to small
group sizes. All statistical analyses were conducted in
IBM SPSS Version 21.
Results
Study numbers
Initial searches returned 972 papers across the five spe-
cies studied. Following application of the two levels of
exclusion criteria (Table 1), 86 papers reporting 126 in-
dividual trials remained for data extraction and analysis
(Table 2, Additional file 2; for full details see 20). Of the
126 trials, 86 (68%) were in the pharmaceutical funding
category, 19 (15%) were in the non-pharmaceutical fund-
ing category and the remaining 21 (17%) were in the ‘no
funding source stated’ category.
Number of outcomes reported
Total number of outcome results
The median total number of outcome results reported
per trial was 5.0, with a large overall range (IQR = 3.0–
11.0, Range = 1.0–36.0, N = 126, Table 3). For individ-
ual funding categories, the highest number of outcomes
reported per trial (N = 9.0) occurred in the non-
pharmaceutical funding category (IQR = 3.0–16.0,
Range = 2.0–24.0) compared to 5.0 (IQR = 3.0–9.3,
Range = 1.0-36.0) in the pharmaceutical category and
6.0 (IQR = 2.5–14.5, Range = 1.0–26.0) in the ‘no
Table 2 Number and funding source of papers and individual trials following level 2 exclusion criteria application
Number of cat
papers (trials)
Number of dog
papers (trials)
Number of horse
papers (trials)
Number of cattle
papers (trials)
Number of sheep
papers (trials)
Total number of
papers (trials, %
of total trials)
Papers including pharmaceutical
agent RCTs
17 49 28 61 17 172
Papers excluded from analysis 9 21 17 29 10 86
Papers analysed 8 (9 trials) 28 (44 trials) 11 (11 trials) 32 (36 trials) 7 (26 trials) 86 (126 trials)
Funding sources of analysed papers
Pharmaceutical company funded/
pharmaceutical company involvement
4 (5 trials) 17 (33 trials) 4 (4 trials) 20 (23 trials) 2 (21 trials) 47 (86 trials; 68%)
Non pharmaceutical funding stated 3 (3 trials) 4 (4 trials) 2 (2 trials) 6 (7 trials) 3 (3 trials) 18 (19 trials; 15%)
No funding stated 1 (1 trial) 7 (7 trials) 5 (5 trials) 6 (6 trials) 2 (2 trials) 21 (21 trials; 17%)
Included studies are the pharmaceutical agent RCTs. Table reproduced from REF companion manuscript
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funding source declared’ category. The differences be-
tween funding categories were not significant
(p = 0.133).
Number of unique outcome measures
Overall, the median number of unique outcome measures
per trial (discounting instances where the same outcome
measure was recorded more than once) were lower but
largely similar to the results for the total number of
outcomes reported (Median = 5.0, IQR = 3.0–8.0,
Range = 1.0–36.0, Additional file 2: Table S1). The
differences between funding categories were not significant
(p = 0.26).
Primary outcome identification
Overall, 51 out of the 126 trials (40.5%) defined a pri-
mary outcome (Table 4). A significantly larger propor-
tion of all trials within the pharmaceutical funding
category identified a primary outcome compared to the
other funding groups (P = 42/86, 48.8%; NP = 4/19,
21.1%; NF = 5/21, 23.8%; p = 0.01). The proportions of
trials defining a primary outcome did vary from this pat-
tern across the different species, with sheep having the
largest proportion of trials identifying a primary out-
come, and horses the lowest (Table 4).
Number of animals per trial
Overall the median number of animals enrolled per trial
was 30, with a large associated range (IQR = 17.5–98.8,
Range = 5–5996, Table 5). The median number of ani-
mals enrolled per trial was broadly similar and not sig-
nificantly different between all the funding categories
(P = 30.0, NP = 24.0, NF = 42.0, p = 0.302; Table 5). The
number of animals enrolled per trial was similar across
all the species examined except for cattle where it was
noticeably higher (cats = 32.0, dogs = 27.5, horses = 26.0,
cattle = 233.0 and sheep = 20.0; Table 5).
Sample size calculations
Within the 126 trials, only 18 (14.3%) reported perform-
ing a sample size calculation. The proportions of trials
across the funding groups reporting a sample size calcu-
lation were low and very similar, with no statistical dif-
ference across the funding groups (PH = 12/86, 14.0%;
NP = 3/19, 15.8%; NF = 3/21, 14.3%, p = 0.9). Again,
there were differences across the species in the propor-
tions within each category ranging from 0% of sheep tri-
als, to 27.8% of cattle trials reporting a sample size
calculation (Table 6).
Discussion
This sample of 126 veterinary RCTs reported multiple
outcomes (median of 5 per trial) assessed on a relatively
Table 3 Number of outcomes reported per trial for funding categories and individual species
Median Interquartile range Range
Species Cats (N = 9) 10.0 5.5–14.0 2.0–24.0
Dogs (N = 44) 4.5 2.0–5.0 1.0–36.0
Horses (N = 11) 12.0 7.0–14.0 1.0–26.0
Cattle (N = 36) 5.5 3.0–11.8 1.0–36.0
Sheep (N = 26) 5.0 3.0–8.5 1.0–18.0
Funding category Trials with pharmaceutical funding/
involvement (N = 86)
5.0 3.0–9.3 1.0–36.0
Trials with non-pharmaceutical funding
stated (N = 19)
9.0 3.0–16.0 2.0–24.0
Trials with no funding source stated
(N = 21)
6.0 2.5–14.5 1.0–26.0
All funding categories and species combined All trials (N = 126) 5.0 3.0–11.0 1.0–36.0
Table 4 Number and percentages of trials identifying a primary outcome for individual species and funding categories
Trials with pharmaceutical funding/
involvement
Trials with non-pharmaceutical
funding stated
Trials with no funding source
stated
All trials
Cats 2/5 (40%) 1/3 (33.3%) 1/1 (100%) 4/9 (44.4%)
Dogs 8/33 (24.2%) 2/4 (50%) 1/7 (14.3%) 11/44 (25%)
Horses 2/4 (50%) 0/2 (0%) 0/5 (0%) 2/11 (18.2%)
Cattle 11/23 (47.8%) 1/7 (14.3%) 2/6 (33.3%) 14/36 (38.9%)
Sheep 19/21 (90.5%) 0/3 (0%) 1/2 (50%) 20/26 (76.9%)
All species 42/86 (48.8%) 4/19 (21.1%) 5/21 (23.8%) 51/126 (40.5%)
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small number of (median 30) animals per trial. Less than
half of the trials specified a primary outcome in their
materials and methods and sample size calculations were
rarely performed. Of these measures only whether a pri-
mary outcome measure was defined or not was signifi-
cantly affected by the source of funding.
The influence that the source of funding has on the
reporting of RCTs was recently reported in a related
manuscript [8] and it was found that trials with pharma-
ceutical company involvement were more likely to have
positive outcomes of treatment (sponsorship bias) Ware-
ham et al. found that across all trials, regardless of fund-
ing, it was found that due to poor reporting and/or
conduct of the trials an unclear risk of bias was highly
prevalent [8]. In the current study only whether a pri-
mary outcome was reported or not seemed to be signifi-
cantly affected by funding source. However the current
study is a descriptive hypothesis generating study and
the number of trials in some of the funding categories
may be subject to both Type I and Type II errors. The
reasons behind why funding source may affect how out-
comes are measured and reported and the size of trials
are unclear. In medical RCTs, there has been some sug-
gestion that funding source may influence the size of tri-
als across a number of different pharmaceutical, surgical
and nursing interventions, so further investigation in the
veterinary field may be warranted [9–11].
A median value of 5 outcomes per trial is lower than
has been previously reported in similar studies of veter-
inary clinical trials. Other reports include a mean of 10.8
outcomes per trial in a study examining dog and cat
clinical trials [5], and a median of 8.5 outcomes per trial
in livestock clinical trials [3]. These studies were pub-
lished in 2010 and 2009 respectively and a comparison
of their results with the ones in this study could be
interpreted as a general reduction in the number of out-
comes reported per trial over time. Alternatively, meth-
odological differences between the previous studies and
this one could explain the findings. For example, the
studies all include differing subsets of literature (e.g.
clinical trials versus RCTs, any intervention versus
pharmaceutical interventions only, different ranges of
species included) and employ different data extraction
methods. Interestingly, the non-pharmaceutical funding
group in the current study had a similar median number
of outcomes per trial (9.0) to these previous studies, with
the pharmaceutical funding group having a lower me-
dian (5.0), although the ranges are wide and differences
not significant within this sample. The maximum num-
ber of outcomes reported per trial was 36. One concern
with having large numbers of outcomes in a trial is that
statistically, the ability to accurately detect a difference
between two groups diminishes as an increasing number
of statistical tests are performed on a limited amount of
Table 5 Numbers of animals enrolled per trial for individual species and funding categories
Median Interquartile range Range
Species Cats (N = 9) 32.0 21.5–93.0 16.0–121.0
Dogs (N = 44) 27.5 16.0–43.0 5.0–316.0
Horses (N = 11) 26.0 15.0 – 61.0 6.0–373.0
Cattle (N = 36) 233.0 35.0–943.0 8.0–5996.0
Sheep (N = 26) 20.0 19.0–24.8 10.0–655.0
Funding category Trials with pharmaceutical funding/
involvement (N = 86)
30.0 19.8–125.8 7.0–5996.0
Trials with non-pharmaceutical funding
stated (N = 19)
24.0 14.0–69.0 8.0–369.0
Trials with no funding source stated
(N = 21)
42.0 16.0–75.0 5.0–1031.0
All funding categories and species combined All trials (N = 126) 30.0 17.5–98.8 5.0–5996.0
Table 6 Numbers and percentages of trials reporting sample size calculations for individual species and funding categories
Trials with pharmaceutical funding/
involvement
Trials with non-pharmaceutical
funding stated
Trials with no funding source
stated
All trials
Cats 1/5 (20%) 0/3 (0%) 1/1 (100%) 2/9 (22.2%)
Dogs 2/33 (6.1%) 2/4 (50%) 1/7 (14.3%) 5/44 (11.4%)
Horses 0/4 (0%) 0/2 (0%) 1/5 (20%) 1/11 (9.1%)
Cattle 9/23 (39.1%) 1/7 (14.3%) 0/6 (0%) 10/36 (27.8%)
Sheep 0/21 (0%) 0/3 (0%) 0/2 (0%) 0/26 (0%)
All 12/86 (14.0%) 3/19 (15.8%) 3/21 (14.3%) 18/126 (14.3%)
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data (and number of subjects), that is, the chance of
introducing ‘error’ into the results increases [12]. How-
ever, if a trial is well designed and adequately powered a
primary outcome and a number of secondary outcomes
can be investigated if the sample size, statistical analysis
are appropriate. In this study, trials involving cats and
horses appeared to have a higher median number of out-
comes per trial compared to the other species; however
the small sample sizes make drawing conclusions from
this problematic.
Selecting and properly defining a primary outcome (in
advance of conducting a trial) is extremely important, and
is outlined in the CONSORT RCT reporting guideline
and the adapted livestock version REFLECT [1, 13, 14]. In
the current study, 40% of trials specified a primary out-
come and trials in the pharmaceutical funding category
more frequently identified a primary outcome compared
to the other groups. Previous studies have reported
extremely varied findings on this topic with the number of
trials defining a primary outcome varying from 86% of
small animal RCTs [4] to 7% in dog and cat clinical trials
[5]. If primary and secondary outcomes are not pre-
specified and adhered to, there is the risk that throughout
a trial, the most ‘interesting’ results can be reported rather
than those the trial was designed to address. On the other
hand, outcomes that prove to be ‘negative’ in respect to
the treatment of interest may not be reported, biasing the
evidence base. Such ‘outcome switching’ is currently being
tracked in human trials literature by the COMPARE initia-
tive [15]. Without a trials registry, where protocols can be
made available before a trial begins, it is extremely difficult
to track and address this issue.
Primary outcomes are also important as they are the
measures used to determine the number of animals re-
quired for the trial, via a sample size calculation. The
low percentage of authors reporting that they have
undertaken a sample size calculation in this study is
actually higher than previously found; reports have var-
ied from 0 to 18% [3–7] which again could reflect a
genuine improvement over time, or a difference in the
sample of literature studied. The number of animals
actually enrolled per trial encompassed a very large
range (5-5996) with noticeably higher numbers of
animals enrolled in cattle trials compared to the other
species potentially reflecting the easier recruitment of
large numbers of animals within herds to a trial. When a
sample size calculation is not reported, the reader can-
not easily identify if the number of subjects in the trial
was sufficient to detect a difference between two inter-
vention groups, even if such a difference exists [16], or if
the identification of a difference between two groups is
reliable. Conversely, excessively large sample sizes are an
ethical concern as more participants are exposed to
potential risks than is necessary [2, 16]. Whilst an
adequately powered study is the ideal situation, there are
advocates of the theory that some evidence is better than
no evidence, and smaller trials can be performed and
later combined in evidence syntheses to contribute sub-
stantially to the evidence base. There are certain caveats
to this approach, which are that trials must be of sound
methodological design to eliminate bias, and it is ex-
tremely important that all trials are published so they
are available for evidence synthesis [17].
The proportions of trials defining a primary outcome,
and particularly those reporting a sample size calcula-
tion, were vastly lower in the current study, and others
in the veterinary literature, compared to those in the
medical literature [18]. There are still huge improve-
ments to be made; one way of improving how well veter-
inary RCTs are reported is through the endorsement and
increased awareness of relevant reporting guidelines (e.g.
CONSORT, REFLECT) by both authors and journals.
Another approach to improve trial conduct, increase the
transparency of RCTs, and reduce publication bias, is
through compulsory registration of trial protocols, as ad-
vocated by the ‘All-Trials’ and ‘Veterinary All-Trials’
campaigns (www.alltrials.net), [19]. A veterinary clinical
trials unit comprising a large network of practices would
also be of huge benefit to the veterinary profession. It
would enable access to large numbers of patients, re-
cords and provide centralised expertise and advice allow-
ing the generation of high quality, relevant evidence. A
cross-discipline approach where academia and industry
work more closely together could also be beneficial for
raising the overall standards of veterinary trials.
Strengths and limitations
To the authors knowledge, in veterinary medicine no-
one has yet investigated the role of funding on the
reporting of outcomes and size of RCTs involving veter-
inary species. This unique manuscript compliments
Wareham et al. [12] and describes the potential role of
funding in study design. The manuscript also provides
further insight into outcome reporting and size of trials
on a different sample of veterinary RCTs compared to
those already published [3–7].
One major limitation of this study is the imbalance in
trial numbers across the funding categories due to the
large proportion of trials in the pharmaceutical funding
group, resulting in the number of trials in the non-
pharmaceutical funding group and the ‘no funding
source declared’ group being relatively small. Of particu-
lar concern is that studies encompassing more than one
trial (for example, one sheep study comprised 19 indi-
vidual trials) tended to be in the pharmaceutical funding
category and could have caused clustering of the data.
Another limitation is that authors were not blinded to
manuscript details while extracting data. Time and
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financial constraints limited this study to one calendar
year of publications, which did not yield enough trials to
rule exclude the possibility of Type II errors hence this
is primarily a descriptive report of these RCTs. Hence a
larger study, powered using the data from this study in-
corporating more years of publications would be benefi-
cial; in particular this could allow potential species
specific differences to be explored. In addition, only
Medline was searched and it has been shown previously
that Medline does not include all clinical veterinary lit-
erature [20] however, it does have functionality that en-
ables RCTs to be identified. This does mean that not all
trials in 2011 that met our inclusion criteria would have
been found. An inherent problem for all studies investi-
gating the quality of veterinary RCTs is the reliance on
good reporting to enable the investigators to adequately
analyse the trials.
Conclusions
The results of this study are important to those who use
the results of pharmaceutical trials to inform practice
and to researchers undertaking RCTs with veterinary
species. The findings contribute to the body of know-
ledge indicating that veterinary clinical trials could be
substantially improved in terms of reporting, and almost
certainly design and execution, irrespective of funding
source. It is difficult to accurately assess the true
strength of trial conduct when they are poorly reported.
Ultimately, the low quantity and quality of evidence
available to veterinary practitioners severely inhibits our
ability to practice in an evidence-based way; improve-
ments are essential to ensure the veterinary profession
has a sound scientific knowledge base on which to make
clinical decisions, ensuring the best care for patients.
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